Patent thickets extend market exclusivity, delaying generic competition and increasing drug costs, with $3.5 billion in excess spending identified for four drugs over two years. The study found that ...
The Hatch-Waxman Act seeks to strike a balance in the pharmaceutical industry by incentivizing drugs makers to develop innovative drugs with additional patent protections while also providing ...